Pharma Business International | The voice of the Pharma industry

R&D

GSK and University of Oxford collaborate to advance novel cancer research

28th January 2025

GSK and the University of Oxford have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer Immuno-Prevention Programme will conduct translational...

MANUFACTURING

Upperton Pharma Solutions completes build of new £7m sterile manufacturing facility

R&D

Cancer Research Horizons and Lifebit to maximise impact of research data

View the Online Magazine

Latest Issue

Magazine Archive

Launches

Pioneer Group drives AI innovation in healthcare through industry and academic collaboration

Pioneer Group, the life science infrastructure and venture building specialist, has joined forces with Innovate UK, The Medical Research Council (MRC) and AstraZeneca, to...

New SWLP laboratory at Croydon Hospital transforms the diagnostic facility into one of the most advanced and innovative in the UK

South West London Pathology (SWLP) introduces cutting-edge technologies to its laboratories to create one of the most modern, innovative, and efficient clinical blood science...

Amazon Filters launches high-temp vent filter for pharma and biotech

A UK process filter manufacturer has launched an enhanced high-temperature-resistant membrane product aimed at vent applications across the global pharmaceutical and biotechnology markets. Amazon Filters’...

Suppliers Guide

Check out our Suppliers Guide or contact our team and get your company listed

Keep up with what's happening in the industry and subscribe to our weekly newsletter

Events

Get your event seen by potential candidates on the world's leading industry site.

Supply Chain

Er-Kim signs distribution agreement with the MEDICE Health Family for Vafseo in Central & Eastern Europe

Er-Kim, an international company specializing in the commercialization of novel therapies for pharmaceutical and biopharmaceutical companies, has signed a distribution agreement with the MEDICE...

Er-Kim extends exclusive distribution agreement with Ascendis to expand commercialization of endocrinology portfolio

Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, has extended its exclusive agreement with Danish biopharmaceutical company Ascendis Pharma to commercialize...

Camida wins Pharma Supplier of the Year!

The much-coveted title, Pharma Supplier of the Year, was bestowed upon Camida at the 2024 Pharma Industry Awards. (Wednesday, 30 October / Dublin, Ireland) Camida...

AscellaHealth acquires CHAPPER healthcare

AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, has acquired CHAPPER healthcare, a global specialty pharmaceutical wholesaler, distributor and...

Approvals

Takeda’s FRUZAQLA gains Health Canada market authorization for metastatic colorectal cancer

Health Canada has provided market authorization for Takeda Canada's FRUZAQLA (fruquintinib capsules), indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC)...

European Commission expands Jemperli plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer

The European Commission has approved GSK's Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or...

Datroway approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Sarclisa approved in EU as first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

FDA approves LUMAKRAS in combination with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer

AstraZeneca’s Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma

Manufacturiung

MANUFACTURING

Upperton Pharma Solutions completes build of new £7m sterile manufacturing facility

UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions, has completed the build of its new sterile manufacturing facility in Nottingham, UK. The new...

Viralgen and Axovia to manufacture investigational gene therapy for retinal dystrophy in Bardet-Biedl Syndrome patients

ACG expands global footprint with new capsule manufacturing facility in Thailand

$3bn expansion for Lilly’s recently acquired manufacturing facility in Wisconsin

Cell and Gene Therapy Catapult and UCL Researcher-in-Residence to develop digital twin of CAR-T manufacturing

Process filter maker creates new global pharma and healthcare role

Finance

Daiichi Sankyo acquires intellectual property rights for anti-TA-MUC1 antibody in DS-3939 from Glycotope

Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program

Johnson & Johnson strengthens neuroscience position with acquisition of Intra-Cellular Therapies

GSK to acquire IDRx

Research & Development
Latest

R&D

GSK and University of Oxford collaborate to advance novel cancer research

28th January 2025

GSK and the University of Oxford have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer...

R&D

Cancer Research Horizons and Lifebit to maximise impact of research data

28th January 2025

Cancer Research Horizons has joined Lifebit’s Federated Data Network to help maximise the impact of data generated through Cancer Research UK-funded research. This federated network...

R&D

AbbVie and Neomorph to develop molecular glue degraders for oncology and immunology

27th January 2025

AbbVie and Neomorph have announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology. Molecular glue...

R&D

Zai Lab receives U.S. FDA Orphan Drug Designation for small cell lung cancer treatment

24th January 2025

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Zai Lab's ZL-1310, a potential highly active first-in-class DLL3 antibody-drug...

R&D

Cancer Research UK, Cytovation and the Norwegian Cancer Society to advance rare cancer treatment

23rd January 2025

Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase 2...